Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MCHR1 | Q99705 | 2/20 | 0.62 |
| ▸ | SIGMAR1 | Q99720 | 3/20 | 0.61 |
| ▸ | MEN1 | O00255 | 1/20 | 0.59 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.59 |
| ▸ | CCR3 | P51677 | 2/20 | 0.52 |
| ▸ | MAOA | P21397 | 1/20 | 0.51 |
| ▸ | MAOB | P27338 | 1/20 | 0.51 |
| ▸ | UTS2R | Q9UKP6 | 2/20 | 0.51 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.50 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.50 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.50 |
| ▸ | CCR1 | P32246 | 1/20 | 0.49 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4199167 | 0.89 | SIGMAR1 (0.68) | MCHR1SIGMAR1MEN1KMT2ACCR3 | |
| SCHEMBL4031569 | 0.84 | SIGMAR1 (0.67) | MCHR1SIGMAR1MEN1KMT2ACCR3 | |
| SCHEMBL4205680 | 0.84 | MCHR1 (0.49) | MCHR1SIGMAR1MEN1KMT2ACCR3 | |
| SCHEMBL12511780 | 0.84 | SIGMAR1 (0.61) | MCHR1SIGMAR1MEN1KMT2ACCR3 | |
| SCHEMBL2215875 | 0.83 | SIGMAR1 (0.60) | MCHR1SIGMAR1MEN1KMT2ACCR3 | |
| SCHEMBL4170568 | 0.81 | ADIPOR2 (0.58) | MCHR1SIGMAR1MEN1KMT2ACCR3 | |
| SCHEMBL7487718 | 0.81 | SIGMAR1 (0.74) | MCHR1SIGMAR1MEN1KMT2ACCR3 | |
| SCHEMBL4202919 | 0.80 | SIGMAR1 (0.70) | MCHR1SIGMAR1MEN1KMT2ACCR3 | |
| SCHEMBL4034199 | 0.80 | SIGMAR1 (0.73) | MCHR1SIGMAR1MEN1KMT2ACCR3 | |
| SCHEMBL2211108 | 0.80 | UTS2R (0.62) | MCHR1SIGMAR1MEN1KMT2ACCR3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090012125-A1 | Piperidine Derivatives, Their Process for Preparation, Their Use as Therapeutic Agents and Pharmaceutical Compositions Containing Them | CAGE PETER | 2009-01-08 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090012125-A1 | Piperidine Derivatives, Their Process for Preparation, Their Use as Therapeutic Agents and Pharmaceutical Compositions Containing Them | CCR3, CCR1, CCR5 | MCHR1 1981/4885SIGMAR1 1718/4885MEN1 3868/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.